Joenja Tablet, Film Coated
NDC Package 71274-170-60

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Joenja (leniolisib) tablets is jOENJA is indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. This formulation utilizes a tablet, film coated delivery system. Marketed by Pharming Healthcare Inc., this product is identified by NDC 71274-170 and is authorized under FDA application NDA217759.

Identification & Billing

NDC Package Code
71274-170-60
Package Description
1 BOTTLE, PLASTIC in 1 CARTON / 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC
Product Code
71274-170
11-Digit Billing Format
71274017060
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Joenja
Non-Proprietary Name
Leniolisib
Substance Name
Leniolisib Phosphate
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
LENIOLISIB PHOSPHATE 70 mg/1
Pharmacologic Class
Usage Information
JOENJA is indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.

Regulatory & Marketing

Labeler Name
Pharming Healthcare Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA217759
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
03-29-2023
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 71274-170-60 identifies a specific commercial package of 1 bottle, plastic in 1 carton / 60 tablet, film coated in 1 bottle, plastic of Joenja, a human prescription drug labeled by Pharming Healthcare Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This tablet, film coated is formulated for oral use and contains leniolisib phosphate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Pharming Healthcare Inc. on March 29, 2023. The current certification is valid through December 31, 2026.

How is this Pharming Healthcare Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 71274017060. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
71274-170-60
11-Digit CMS (5-4-2)
71274-0170-60

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.